Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=ODKSFYDXXFIFQN-BYPYZUCNSA-N
InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
44.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Page: p.621Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: Page: p.63 |
unhealthy, 24 n = 11 Health Status: unhealthy Condition: Cystic fibrosis Age Group: 24 Sex: M+F Population Size: 11 Sources: Page: p.63 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: Page: p.1 |
healthy, 34 ± 2.6 n = 12 Health Status: healthy Condition: Dietary supplementation Age Group: 34 ± 2.6 Sex: M+F Population Size: 12 Sources: Page: p.1 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: Page: p.200 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
PubMed
Title | Date | PubMed |
---|---|---|
Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families. | 2001 |
|
Novel mutations in the GALK1 gene in patients with galactokinase deficiency. | 2001 |
|
Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. | 2001 |
|
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. | 2001 |
|
Hemodialysis techniques and advanced glycation end products. | 2001 |
|
AGE in micro- and macroangiopathy. | 2001 |
|
Signal-binding specificity of the mu4 subunit of the adaptor protein complex AP-4. | 2001 Apr 20 |
|
Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. | 2001 Feb 2 |
|
Amino acid residues outside of the pore region contribute to N-type calcium channel permeation. | 2001 Feb 23 |
|
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. | 2001 Feb 23 |
|
Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation. | 2001 Feb 9 |
|
Current strategies for the management of neonatal urea cycle disorders. | 2001 Jan |
|
Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. | 2001 Jan |
|
Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. | 2001 Jan |
|
Relationship between flow rate and NO production in postnatal mesenteric arteries. | 2001 Jan |
|
Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system. | 2001 Jan |
|
Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. | 2001 Jan |
|
Buffering action of endogenous nitric oxide on the adrenocortical secretagogue effect of endothelins in the rat. | 2001 Jan |
|
The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. | 2001 Jan |
|
Nitric oxide production by coelomocytes of Asterias forbesi. | 2001 Jan |
|
Substitution of Asp114 or Arg116 in the fingers domain of moloney murine leukemia virus reverse transcriptase affects interactions with the template-primer resulting in decreased processivity. | 2001 Jan 12 |
|
Specific interactions at the regulatory domain-substrate binding domain interface influence the cooperativity of inhibition and effector binding in Escherichia coli D-3-phosphoglycerate dehydrogenase. | 2001 Jan 12 |
|
Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. | 2001 Jan 15 |
|
Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. | 2001 Jan 19 |
|
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I. | 2001 Jan 5 |
|
C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production. | 2001 Jan 9 |
|
Acetaldehyde, a metabolite of ethanol, activates the hypothalamic-pituitary-adrenal axis in the rat. | 2001 Jan-Feb |
|
Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock. | 2001 Mar 16 |
|
Identification and analysis of the acyl carrier protein (ACP) docking site on beta-ketoacyl-ACP synthase III. | 2001 Mar 16 |
|
Identification of the collagen-binding site of the von Willebrand factor A3-domain. | 2001 Mar 30 |
|
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa. | 2001 Mar 9 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/l-arginine.html
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:02:28 GMT 2023
by
admin
on
Fri Dec 15 15:02:28 GMT 2023
|
Record UNII |
94ZLA3W45F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
54092-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
27974-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
26985-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
55911-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
27296-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
32226-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1895-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
DSLD |
2368 (Number of products:1422)
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
32225-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
15136-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47566-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
WHO-ATC |
B05XB01
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
16401-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22656-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
DSLD |
116 (Number of products:647)
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
FDA ORPHAN DRUG |
785420
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
30062-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
43927-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
53398-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47563-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47568-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47565-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25861-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47564-0
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25322-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
13387-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
13708-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
53200-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22697-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25860-8
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1891-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
JECFA EVALUATION |
L-ARGININE
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1892-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
20637-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
41168-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
56672-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
75214-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1893-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1894-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
44299-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47562-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22727-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
15140-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47567-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16467
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
100000086598
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1711
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
m2040
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB20033
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
29952
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
94ZLA3W45F
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
317
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
7274
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
206269
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
6322
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1426
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
C62008
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
32682
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
SUB05560MIG
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
124
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
D001120
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
DB00125
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
ARGININE
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
94ZLA3W45F
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1485
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1042500
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1091
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
29016
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
74-79-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1429
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
DTXSID6041056
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
200-811-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
32696
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
290
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SUBSTRATE -> TARGET |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |